Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor

A comprehensive review of literature

Antongiulio Faggiano, Pasqualino Malandrino, Roberta Modica, Daniela Agrimi, Maurizio Aversano, Vincenzo Bassi, Ernesto A. Giordano, Valentina Guarnotta, Francesco A. Logoluso, Erika Messina, Vincenzo Nicastro, Vincenzo Nuzzo, Marcello Sciaraffia, Annamaria Colao

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background. Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs. PatientsandMethods. Asystematicreviewof thepublisheddata was performed concerning the use of everolimus in extrapancreaticNET, with theaimofsummarizing thecurrent knowledgeonits efficacy and tolerability. Moreover, the usefulness of everolimus was evaluated according to the different sites of the primary. Results. The present study included 22 different publications, including 874 patients and 456 extrapancreatic NETs treated with everolimus. Nine different primary sites of extrapancreatic NETs were found. The median progression-free survival ranged from 12.0 to 29.9months.Themedian time to progression was not reached in a phase II prospective study, and the interval to progression ranged from 12 to 36 months in 5 clinical cases. Objective responses were observed in 7 prospective studies, 2 retrospective studies, and 2 case reports. Stabilization of the disease was obtained in a high rate of patients, ranging from 67.4% to 100%. The toxicity of everolimus in extrapancreatic NETs is consistent with the known safety profile of the drug. Most adverse events were either grade 1 or 2 and easy manageable with a dose reduction or temporary interruption and only rarely requiring discontinuation. Conclusion. Treatment with everolimus in patients with extrapancreatic NETs appears to be a promising strategy that is safe and well tolerated.The use of this emerging opportunity needs to be validated with clinical trials specifically designed on this topic.

Original languageEnglish
Pages (from-to)875-886
Number of pages12
JournalOncologist
Volume21
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Neuroendocrine Tumors
Safety
Prospective Studies
Sirolimus
Disease-Free Survival
Publications
Everolimus
Retrospective Studies
Clinical Trials
Therapeutics
Pharmaceutical Preparations

Keywords

  • Efficacy
  • Everolimus
  • Extrapancreatic neuroendocrine tumors
  • Neuroendocrine tumors
  • Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Faggiano, A., Malandrino, P., Modica, R., Agrimi, D., Aversano, M., Bassi, V., ... Colao, A. (2016). Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: A comprehensive review of literature. Oncologist, 21(7), 875-886. https://doi.org/10.1634/theoncologist.2015-0420

Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor : A comprehensive review of literature. / Faggiano, Antongiulio; Malandrino, Pasqualino; Modica, Roberta; Agrimi, Daniela; Aversano, Maurizio; Bassi, Vincenzo; Giordano, Ernesto A.; Guarnotta, Valentina; Logoluso, Francesco A.; Messina, Erika; Nicastro, Vincenzo; Nuzzo, Vincenzo; Sciaraffia, Marcello; Colao, Annamaria.

In: Oncologist, Vol. 21, No. 7, 01.07.2016, p. 875-886.

Research output: Contribution to journalReview article

Faggiano, A, Malandrino, P, Modica, R, Agrimi, D, Aversano, M, Bassi, V, Giordano, EA, Guarnotta, V, Logoluso, FA, Messina, E, Nicastro, V, Nuzzo, V, Sciaraffia, M & Colao, A 2016, 'Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: A comprehensive review of literature', Oncologist, vol. 21, no. 7, pp. 875-886. https://doi.org/10.1634/theoncologist.2015-0420
Faggiano, Antongiulio ; Malandrino, Pasqualino ; Modica, Roberta ; Agrimi, Daniela ; Aversano, Maurizio ; Bassi, Vincenzo ; Giordano, Ernesto A. ; Guarnotta, Valentina ; Logoluso, Francesco A. ; Messina, Erika ; Nicastro, Vincenzo ; Nuzzo, Vincenzo ; Sciaraffia, Marcello ; Colao, Annamaria. / Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor : A comprehensive review of literature. In: Oncologist. 2016 ; Vol. 21, No. 7. pp. 875-886.
@article{2bc8673d585444a48aa6a7f39aa2c611,
title = "Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: A comprehensive review of literature",
abstract = "Background. Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs. PatientsandMethods. Asystematicreviewof thepublisheddata was performed concerning the use of everolimus in extrapancreaticNET, with theaimofsummarizing thecurrent knowledgeonits efficacy and tolerability. Moreover, the usefulness of everolimus was evaluated according to the different sites of the primary. Results. The present study included 22 different publications, including 874 patients and 456 extrapancreatic NETs treated with everolimus. Nine different primary sites of extrapancreatic NETs were found. The median progression-free survival ranged from 12.0 to 29.9months.Themedian time to progression was not reached in a phase II prospective study, and the interval to progression ranged from 12 to 36 months in 5 clinical cases. Objective responses were observed in 7 prospective studies, 2 retrospective studies, and 2 case reports. Stabilization of the disease was obtained in a high rate of patients, ranging from 67.4{\%} to 100{\%}. The toxicity of everolimus in extrapancreatic NETs is consistent with the known safety profile of the drug. Most adverse events were either grade 1 or 2 and easy manageable with a dose reduction or temporary interruption and only rarely requiring discontinuation. Conclusion. Treatment with everolimus in patients with extrapancreatic NETs appears to be a promising strategy that is safe and well tolerated.The use of this emerging opportunity needs to be validated with clinical trials specifically designed on this topic.",
keywords = "Efficacy, Everolimus, Extrapancreatic neuroendocrine tumors, Neuroendocrine tumors, Safety",
author = "Antongiulio Faggiano and Pasqualino Malandrino and Roberta Modica and Daniela Agrimi and Maurizio Aversano and Vincenzo Bassi and Giordano, {Ernesto A.} and Valentina Guarnotta and Logoluso, {Francesco A.} and Erika Messina and Vincenzo Nicastro and Vincenzo Nuzzo and Marcello Sciaraffia and Annamaria Colao",
year = "2016",
month = "7",
day = "1",
doi = "10.1634/theoncologist.2015-0420",
language = "English",
volume = "21",
pages = "875--886",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "7",

}

TY - JOUR

T1 - Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor

T2 - A comprehensive review of literature

AU - Faggiano, Antongiulio

AU - Malandrino, Pasqualino

AU - Modica, Roberta

AU - Agrimi, Daniela

AU - Aversano, Maurizio

AU - Bassi, Vincenzo

AU - Giordano, Ernesto A.

AU - Guarnotta, Valentina

AU - Logoluso, Francesco A.

AU - Messina, Erika

AU - Nicastro, Vincenzo

AU - Nuzzo, Vincenzo

AU - Sciaraffia, Marcello

AU - Colao, Annamaria

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background. Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs. PatientsandMethods. Asystematicreviewof thepublisheddata was performed concerning the use of everolimus in extrapancreaticNET, with theaimofsummarizing thecurrent knowledgeonits efficacy and tolerability. Moreover, the usefulness of everolimus was evaluated according to the different sites of the primary. Results. The present study included 22 different publications, including 874 patients and 456 extrapancreatic NETs treated with everolimus. Nine different primary sites of extrapancreatic NETs were found. The median progression-free survival ranged from 12.0 to 29.9months.Themedian time to progression was not reached in a phase II prospective study, and the interval to progression ranged from 12 to 36 months in 5 clinical cases. Objective responses were observed in 7 prospective studies, 2 retrospective studies, and 2 case reports. Stabilization of the disease was obtained in a high rate of patients, ranging from 67.4% to 100%. The toxicity of everolimus in extrapancreatic NETs is consistent with the known safety profile of the drug. Most adverse events were either grade 1 or 2 and easy manageable with a dose reduction or temporary interruption and only rarely requiring discontinuation. Conclusion. Treatment with everolimus in patients with extrapancreatic NETs appears to be a promising strategy that is safe and well tolerated.The use of this emerging opportunity needs to be validated with clinical trials specifically designed on this topic.

AB - Background. Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs. PatientsandMethods. Asystematicreviewof thepublisheddata was performed concerning the use of everolimus in extrapancreaticNET, with theaimofsummarizing thecurrent knowledgeonits efficacy and tolerability. Moreover, the usefulness of everolimus was evaluated according to the different sites of the primary. Results. The present study included 22 different publications, including 874 patients and 456 extrapancreatic NETs treated with everolimus. Nine different primary sites of extrapancreatic NETs were found. The median progression-free survival ranged from 12.0 to 29.9months.Themedian time to progression was not reached in a phase II prospective study, and the interval to progression ranged from 12 to 36 months in 5 clinical cases. Objective responses were observed in 7 prospective studies, 2 retrospective studies, and 2 case reports. Stabilization of the disease was obtained in a high rate of patients, ranging from 67.4% to 100%. The toxicity of everolimus in extrapancreatic NETs is consistent with the known safety profile of the drug. Most adverse events were either grade 1 or 2 and easy manageable with a dose reduction or temporary interruption and only rarely requiring discontinuation. Conclusion. Treatment with everolimus in patients with extrapancreatic NETs appears to be a promising strategy that is safe and well tolerated.The use of this emerging opportunity needs to be validated with clinical trials specifically designed on this topic.

KW - Efficacy

KW - Everolimus

KW - Extrapancreatic neuroendocrine tumors

KW - Neuroendocrine tumors

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84978706220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978706220&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0420

DO - 10.1634/theoncologist.2015-0420

M3 - Review article

VL - 21

SP - 875

EP - 886

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -